PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
- None.
- None.
The authorization of the Clinical Trial Application by the UK Medicines & Healthcare products Regulatory Agency for PepGen Inc.'s Phase 2 clinical trial represents a significant milestone in the development of PGN-EDO51 for Duchenne muscular dystrophy (DMD). The potential for accelerated approval, contingent upon favorable study outcomes, underscores the importance of this trial. It's crucial to note that DMD is a rare, genetic disorder characterized by progressive muscle degeneration and weakness. Current treatments are limited and focus mainly on symptom management, making the development of effective therapies a high unmet medical need.
The trial's design, a randomized, double-blind, placebo-controlled study, is the gold standard for determining a drug's efficacy and safety. The dose escalation approach is a common strategy in clinical trials to find the optimal balance between efficacy and safety. It's important to understand that 'exon-skipping' is a technique used in genetic therapy to allow cells to 'skip over' faulty parts of the genetic code, leading to the production of a functional protein—in this case, dystrophin, which is crucial for muscle function and is lacking in DMD patients.
From a research perspective, the trial's results on exon skipping and dystrophin production will be pivotal. These biomarkers are critical for demonstrating the drug's mechanism of action and its potential therapeutic benefit. Safety and tolerability data will also be crucial, as they will inform the risk-benefit profile of PGN-EDO51. The inclusion of both ambulatory and non-ambulatory participants expands the trial's applicability to a broader DMD population.
The advancement of PGN-EDO51 into Phase 2 trials could have significant financial implications for PepGen Inc., particularly if the data supports accelerated approval. Investors often closely monitor clinical trial progress, especially in the biotechnology sector where the development pipeline directly impacts company valuation. The DMD market is currently underserved, with a high demand for effective treatments, which could translate into substantial market potential for PGN-EDO51 if approved.
It is also noteworthy that the biotech industry is characterized by high risk and high reward and the success of clinical trials can lead to considerable stock price volatility. PepGen's stock performance may become increasingly sensitive to trial updates and outcomes. If the CONNECT2-EDO51 trial demonstrates positive results, it could lead to increased investor confidence and potential partnerships or funding opportunities. Conversely, any setbacks could negatively affect the company's financial health and investor sentiment.
Furthermore, the open-label extension of the trial signals a long-term commitment to the drug's development and may be viewed positively by stakeholders interested in the sustained progress of treatments for rare diseases like DMD. The company's ability to navigate regulatory pathways and align with agencies such as the MHRA will be critical in determining the speed and success of the drug's market entry.
The biotech sector is highly competitive and the progression of PepGen's PGN-EDO51 into later-stage clinical trials is a testament to the company's potential to carve out a niche in the neuromuscular and neurological disease market. The DMD treatment landscape is evolving, with gene therapy and novel pharmacological approaches seeking to address the root cause of the disease. The success of PGN-EDO51 in clinical trials could position PepGen as a key player in this specialized field.
The decision of the MHRA to authorize the trial is a positive regulatory development that could influence perceptions of the company's regulatory expertise and the credibility of its research. It's essential to understand that the biotech industry often faces regulatory hurdles that can delay or prevent the commercialization of promising therapies. Thus, such an authorization can be seen as an endorsement of the company's scientific approach and its compliance with stringent regulatory standards.
In assessing the market impact, one should consider the size of the DMD patient population amenable to exon 51-skipping therapies. While DMD is a rare disease, the cumulative global market for effective treatments is substantial. The multinational aspect of the trial also suggests a strategic approach to securing market access across various regions, which could be advantageous for the company's global market prospects.
BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has authorized its Clinical Trial Application (CTA) to initiate the CONNECT2-EDO51 Phase 2 clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) amenable to an exon 51-skipping approach.
“We are excited to take the next step forward in our development of PGN-EDO51, which we believe to be a potentially transformative investigational candidate for people living with DMD and are pleased the MHRA authorized our CTA. We believe this study, together with the data generated in our ongoing CONNECT1-EDO51 trial, could potentially support accelerated approval of EDO51, subject to alignment with regulators,” said James McArthur, Ph.D., President and CEO of PepGen. “We are grateful to continue our work with the DMD community to develop this therapy.”
The CONNECT2-EDO51 Phase 2 clinical trial is a multinational, randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study, that will enroll approximately 20 ambulatory and non-ambulatory boys and young men living with DMD amenable to exon 51-skipping, who are at least six years of age. Participants will receive seven doses of either PGN-EDO51 or placebo at approximately four-week intervals for 24 weeks. Per the protocol, the starting dose will escalate from 5 mg/kg to 10 mg/kg, and potentially higher; the same dose levels are being evaluated in the ongoing CONNECT1-EDO51 trial. Further dose escalation will be determined based on evaluation of safety data from prior dose cohort(s). Participants will provide a muscle biopsy at baseline and then at week 25. The trial will assess exon skipping, dystrophin production, and safety and tolerability. All participants will have the opportunity to participate in an open-label extension.
About PGN-EDO51
PGN-EDO51, PepGen’s lead clinical candidate for the treatment of DMD, utilizes the Company’s proprietary Enhanced Delivery Oligonucleotide (EDO) technology to deliver a therapeutic oligonucleotide that is designed to target the root cause of this devastating disease. PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, an established therapeutic target for approximately
About Duchenne Muscular Dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is an X-linked recessive, progressive, muscle-wasting disease that predominantly affects boys. This debilitating disease is caused by genetic mutations in the gene encoding dystrophin, a protein necessary for normal muscle function, and is one of the most prevalent rare genetic diseases, with an incidence rate of approximately one in every 3,500 to 5,000 male births. DMD is characterized by progressive muscle weakness, which leads to patients losing the ability to walk, a loss of upper body function, cardiac issues and difficulties breathing. DMD is invariably fatal by young adulthood. Despite significant advances in treatments for this devastating disease, current exon skipping therapies are limited by poor delivery to muscle tissue and have yet to establish meaningful clinical benefit for DMD patients.
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the therapeutic potential and safety profile of our product candidates, including PGN-EDO51, our technology, including our EDO platform, the design, initiation and conduct of clinical trials, including the CONNECT1-EDO51 and CONNECT2-EDO51 trials, expected timelines and preliminary data reports from our clinical trials, regulatory interactions, including the development pathway for our product candidates and the potential for an accelerated approval pathway for PGN-EDO51, assuming alignment with regulators, and our financial resources and cash runway.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: delays or failure to successfully initiate or complete our ongoing and planned development activities for our product candidates, including PGN-EDO51; our ability to enroll patients in our clinical trials, including CONNECT1-EDO51 and CONNECT2-EDO51; our interpretation of clinical and preclinical study results may be incorrect, or that we may not observe the levels of therapeutic activity in clinical testing that we anticipate based on prior clinical or preclinical results, including for PGN-EDO51; our product candidates, including PGN-EDO51, may not be safe and effective or otherwise demonstrate safety and efficacy in our clinical trials; adverse outcomes from our regulatory interactions, including delays in regulatory review, clearance to proceed or approval by regulatory authorities with respect to our programs, including clearance to commence planned clinical studies of our product candidates, such as PGN-EDO51, or other regulatory feedback requiring modifications to our development programs, including in each case with respect to CONNECT1-EDO51 and CONNECT2-EDO51; changes in regulatory framework that are out of our control; unexpected increases in the expenses associated with our development activities or other events that adversely impact our financial resources and cash runway; and our dependence on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in our most recent annual report on Form 10-K and quarterly report on Form 10-Q that are filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Investor Contact
Laurence Watts
Gilmartin Group
Media Contact
Sarah Sutton
Argot Partners
FAQ
What is the ticker symbol of PepGen Inc.?
What is the goal of PepGen Inc. with their oligonucleotide therapies?
What is the purpose of the CONNECT2-EDO51 Phase 2 clinical trial?
How many participants will be enrolled in the CONNECT2-EDO51 trial?
What will be assessed during the trial?
